Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study

American Journal of Medicine

Volumn 111, Issue 1, 2001, Pages 10-17

  Kipnes, Mark S ^a,d   Krosnick, Arthur ^b,d   Rendell, Marc S ^c,d   Egan, John W ^d   Mathisen, Annette L ^d   Schneider, Roberta L ^d  

^a Diabetes and Glandular Disease Clinic   (United States)

^b Princeton Diabet Treatm Educ Ctr   (United States)

^c Creighton Diabetes Center   (United States)

^d TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; C-PEPTIDE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0034933056     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00713-6     Document Type: Article

References (29)

1. The pathophysiology of type II (non-insulin-dependent) diabetes mellitus: Implications for treatment
2. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones
3. Mechanisms and clinical effects of thiazolidinediones
4. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells
5. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities
6. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase
7. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys
8. VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: Effects of dietary fructose alone or in combination with pioglitazone
9. Clinical evaluation of an insulin resistance improving drug AD-4833 in patients with non-insulin-dependent diabetes mellitus (NIDDM) on diet therapy alone
10. Clinical evaluation of an insulin resistance improving drug AD-4833 in patients with non-insulin-dependent diabetes mellitus (NIDDM) on diet therapy alone. A placebo-controlled, double-blind clinical study
11. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: A six-month, randomized, placebo-controlled, dose-response study
12. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
14. Oral agent therapy in the treatment of type 2 diabetes
15. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM)
16. Oral hypoglycemic agents
17. Pharmacologic therapy for type 2 diabetes mellitus
18. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy
19. Concomitant administration of an insulin-resistance improving drug, AD-4833, with SU drugs: Influence on the serum concentrations of SU drugs
20. Standards of medical care for patients with diabetes mellitus
21. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
22. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: An overview
23. Therapy for diabetes
24. New drug overview. Pioglitazone hydrochloride
25. Management of dyslipidemia in adults with diabetes
26. Plasma lipids and diabetes mellitus in an adult community
27. Lipids, glucose intolerance and vascular disease: The Framingham Study
28. Rosiglitazone
29. Thiazolidinediones